Biotech

balloon missed target pop arrows miss failure
Biotech

Boehringer's schizophrenia drug fails trio of phase 3 trials

Boehringer’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials.
Gabrielle Masson Jan 16, 2025 11:58am
Photo of white clouds in a blue sky

Servier extends AI drug development pact with Google Cloud

Jan 16, 2025 9:11am
video
Carl Sailer on AI market trends and strategic planning in biotech

Carl Sailer on AI, market trends, and strategic planning in biotech

Oct 28, 2024 8:00pm
White arrow on a road pointing to the rising sun

Avacta hits 10% response rate, adds peptide-drug conjugate arms

Jan 16, 2025 8:51am
video
Guidehouses Karla Anderson shares top tips for successful biotech commercialization

Guidehouse’s Karla Anderson shares top tips for successful biotech commercialization

Oct 28, 2024 8:00am
Biotech CEO Sisterhood JPM25

JPM25 tracker: Fierce Biotech conference roundup

Jan 16, 2025 6:00am